Evrenzo (Roxadustat)
HIF Prolyl Hydroxylase Inhibitor for Anaemia in Chronic Kidney Disease
Quick Facts About Evrenzo
Key Takeaways About Evrenzo (Roxadustat)
- First-in-class oral treatment: Evrenzo is a HIF prolyl hydroxylase inhibitor – a new class of anaemia medication that can be taken by mouth instead of requiring injections like traditional ESAs
- Stimulates natural red blood cell production: It works by mimicking the body’s response to low oxygen, increasing erythropoietin production and improving iron absorption
- Three times weekly dosing: Take on the same three days each week with at least one day between doses – never on two consecutive days
- Important timing with other medications: Must be taken at least 1 hour after phosphate binders or supplements containing calcium, iron, magnesium, or aluminium
- Serious risk of blood clots: Evrenzo carries a risk of thromboembolic events including deep vein thrombosis, pulmonary embolism, and vascular access thrombosis in dialysis patients
What Is Evrenzo and What Is It Used For?
Evrenzo (roxadustat) is an oral medication that increases the number of red blood cells and raises haemoglobin levels in the blood. It is used to treat symptomatic anaemia in adults with chronic kidney disease (CKD), regardless of whether the patient is on dialysis or not.
Anaemia is a common and significant complication of chronic kidney disease. As kidney function declines, the kidneys produce less erythropoietin (EPO), the hormone responsible for stimulating red blood cell production in the bone marrow. This leads to a gradual reduction in red blood cells and haemoglobin, the oxygen-carrying protein within these cells. The resulting anaemia can cause debilitating symptoms including persistent fatigue, weakness, shortness of breath, dizziness, difficulty concentrating, and reduced exercise tolerance.
Evrenzo represents a fundamentally new approach to treating CKD-associated anaemia. It belongs to a class of medications known as hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs). Rather than directly replacing erythropoietin as traditional injectable ESAs do, roxadustat works by stabilising hypoxia-inducible factors (HIFs) – transcription factors that orchestrate the body’s natural response to low oxygen levels. When oxygen is scarce, HIFs normally activate genes that increase erythropoietin production, enhance iron absorption from the gut, and mobilise iron stores for incorporation into new red blood cells.
Under normal oxygen conditions, HIF proteins are rapidly broken down by prolyl hydroxylase enzymes. Roxadustat inhibits these enzymes, allowing HIF to accumulate and trigger the same coordinated erythropoietic response that occurs naturally at high altitude. This mechanism offers several potential advantages: it stimulates erythropoietin production in a more physiological manner (without the supraphysiological EPO peaks seen with injected ESAs), it simultaneously improves iron metabolism (reducing the need for intravenous iron supplementation), and it is administered orally rather than by injection.
Evrenzo was first approved in the European Union in August 2021 by the European Medicines Agency (EMA) for the treatment of symptomatic anaemia in adult patients with CKD. It is also approved in Japan, China, South Korea, and several other countries. In clinical trials involving thousands of patients (the ALPS, ANDES, DOLOMITES, HIMALAYAS, PYRENEES, and ROCKIES studies), roxadustat demonstrated non-inferiority to erythropoiesis-stimulating agents in maintaining haemoglobin levels in both dialysis-dependent and non-dialysis-dependent CKD patients.
Evrenzo is the first HIF-PHI to receive marketing authorisation in the European Union. Unlike traditional ESA injections that require refrigerated storage and healthcare professional administration, Evrenzo tablets can be stored at room temperature and taken at home, offering greater convenience for patients managing chronic kidney disease.
What Should You Know Before Taking Evrenzo?
Before starting Evrenzo, your doctor needs to know about all your medical conditions and medications. Evrenzo is contraindicated if you are allergic to peanuts or soya, during the third trimester of pregnancy, and while breastfeeding. It carries important warnings regarding thromboembolic events, seizures, and cardiovascular risk.
Contraindications
You should not take Evrenzo if any of the following apply to you:
- Allergy to peanuts or soya – Evrenzo contains soya lecithin as an excipient, and there is potential for cross-reactivity with peanut allergy
- Allergy to roxadustat or any other ingredient in this medicine (see the contents section below)
- More than 6 months of pregnancy (third trimester) – Evrenzo may cause harm to the unborn baby. It is also better to avoid this medicine during early pregnancy
- Breastfeeding – it is not known whether roxadustat passes into breast milk and could harm your baby
Warnings and Precautions
Talk to your doctor or pharmacist before taking Evrenzo if you have or have had any of the following conditions:
- Epilepsy or a history of seizures – seizures have been reported as a side effect of Evrenzo and your doctor may need to monitor you more closely or adjust your treatment
- Signs or symptoms of infection – including fever, sweating, chills, sore throat, runny nose, shortness of breath, weakness, confusion, cough, vomiting, diarrhoea, stomach pain, burning sensation when urinating, or skin redness or sores
- Liver disease – hepatic impairment may affect how Evrenzo is metabolised and your doctor may need to adjust your dose
Chronic kidney disease and anaemia can increase the risk of cardiovascular events and life-threatening conditions. It is important that your anaemia is properly treated and monitored. Your doctor will regularly check your haemoglobin levels and adjust your treatment accordingly. Switching between different anaemia treatments may also have a negative impact on your cardiovascular health.
- Blood clots in the leg veins (DVT): pain and/or swelling in the leg, cramp, or warmth in the affected leg
- Blood clots in the lungs (PE): sudden shortness of breath, chest pain that worsens with breathing, anxiety, dizziness, fainting, rapid pulse, or coughing (sometimes with blood)
- Haemodialysis access thrombosis: swelling, redness, hardening around your dialysis port, or inability to feel a vibration (“thrill”) over the access site
- Seizures: convulsions, or warning signs such as headache, irritability, fear, confusion, or unusual sensations
- Signs of stroke: sudden weakness or numbness (especially on one side of the body), sudden confusion, speech difficulty, vision problems, severe headache, loss of coordination or balance
- Signs of severe infection (sepsis): high fever with confusion, rapid breathing, or feeling very unwell
Pregnancy and Breastfeeding
Evrenzo may harm an unborn baby. It is not recommended during the first 6 months of pregnancy and is strictly contraindicated during the last 3 months of pregnancy. Women of childbearing potential must use an effective method of contraception during treatment with Evrenzo and for at least one week after the last dose. If you use a hormonal contraceptive, you must also use a barrier method (such as a condom or diaphragm), as roxadustat may potentially reduce the effectiveness of hormonal contraception.
Do not breastfeed if you are being treated with Evrenzo. It is not known whether roxadustat passes into breast milk, and a risk to the nursing infant cannot be excluded. Your doctor will help you decide whether to discontinue breastfeeding or to discontinue Evrenzo treatment, taking into account the benefit of breastfeeding for the child and the benefit of therapy for you.
Children and Adolescents
Evrenzo should not be given to children or adolescents under 18 years of age. There is insufficient information on the safety and efficacy of roxadustat in this age group. Clinical studies have not been conducted in paediatric patients.
Driving and Operating Machinery
Evrenzo may affect your ability to drive and use machines. Seizures can occur as a side effect of treatment. If you experience seizures, dizziness, or any other symptoms that affect your alertness, do not drive or operate machinery until the symptoms have resolved. Discuss with your doctor whether it is safe for you to drive during treatment.
Important Information About Excipients
Evrenzo contains lactose (a type of sugar), traces of peanut and soya (soya lecithin), and an azo dye (allura red AC aluminium lake, E129). If your doctor has told you that you have an intolerance to certain sugars, or if you are allergic to peanuts, soya, or azo dyes, contact your doctor before taking this medicine.
How Does Evrenzo Interact with Other Drugs?
Evrenzo can interact with several commonly prescribed medications, particularly phosphate binders, statins, probenecid, gemfibrozil, and other anaemia treatments. The most critical interaction involves phosphate binders and mineral supplements, which must be taken at least 1 hour before Evrenzo to avoid reducing its absorption.
Tell your doctor or pharmacist about all medicines you are taking, have recently taken, or might take. Evrenzo can affect how other medicines work, and other medicines can affect how Evrenzo works. Understanding these interactions is crucial for safe and effective treatment.
Major Interactions
| Drug / Supplement | Category | Effect | Recommendation |
|---|---|---|---|
| Phosphate binders (sevelamer, calcium acetate) | CKD management | Multivalent cations bind to roxadustat in the gut, preventing proper absorption | Take Evrenzo at least 1 hour after phosphate binders |
| Calcium, iron, magnesium, or aluminium supplements | Mineral supplements | Multivalent cations reduce roxadustat absorption significantly | Take Evrenzo at least 1 hour after these supplements |
| Erythropoiesis-stimulating agents (ESAs) | Anaemia treatment | Concurrent use may cause excessive red blood cell production and dangerously high haemoglobin levels | Do not use Evrenzo concurrently with ESAs |
| Probenecid | Gout treatment | Inhibits roxadustat metabolism, increasing drug exposure | Your doctor may prescribe an alternative or adjust dosing |
Moderate Interactions
| Drug | Category | Effect | Recommendation |
|---|---|---|---|
| Simvastatin | Cholesterol-lowering (statin) | Roxadustat may increase simvastatin exposure via OATP1B1 inhibition | Monitor for statin-related side effects; dose adjustment may be needed |
| Atorvastatin | Cholesterol-lowering (statin) | Roxadustat may increase atorvastatin exposure | Monitor closely for muscle pain or weakness |
| Rosuvastatin | Cholesterol-lowering (statin) | Increased rosuvastatin levels via BCRP and OATP1B1 inhibition | Your doctor may switch to a different statin or reduce the dose |
| Gemfibrozil | Lipid-lowering (fibrate) | May increase roxadustat exposure via CYP2C8 inhibition | Your doctor may prescribe an alternative during Evrenzo therapy |
If you usually take any of the medications listed above, your doctor may prescribe an alternative medicine during your treatment with Evrenzo, or may adjust the doses of your current medications. Always inform your doctor about all prescription medications, over-the-counter drugs, and supplements you are taking before starting Evrenzo.
What Is the Correct Dosage of Evrenzo?
Evrenzo is taken three times per week as a tablet, never on two consecutive days. The starting dose is determined by your doctor based on your weight and whether you have previously received ESA therapy. Your doctor will regularly monitor your haemoglobin and adjust the dose accordingly. Doses range from 20 mg to a maximum of 400 mg three times per week.
Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. Your doctor will determine your individual starting dose and adjust it over time based on your haemoglobin response.
How to Take Evrenzo
Administration Instructions
- Take your dose of Evrenzo three times per week, unless your doctor instructs otherwise
- Never take Evrenzo on two consecutive days
- Take Evrenzo on the same three days each week (e.g. Monday, Wednesday, Friday)
- Evrenzo can be taken with food or between meals
- Swallow the tablets whole – do not chew, split, or crush them
- Take Evrenzo at least 1 hour after phosphate binders or supplements containing calcium, iron, magnesium, or aluminium
Adults – Dose Range
Starting Dose (Determined by Your Doctor)
Not previously on ESA therapy: The starting dose depends on your body weight and haemoglobin levels. Your doctor will select the appropriate starting dose.
Switching from ESA therapy: Your doctor will calculate the starting dose based on the average weekly ESA dose you were receiving.
Dose range: 20 mg to 400 mg three times per week
Dose adjustments: Your doctor will check your haemoglobin regularly and may increase or decrease your dose to keep your haemoglobin within the target range.
Reduced Dosing Schedules
In rare cases, based on your haemoglobin levels, your doctor may reduce the frequency of Evrenzo to twice or even once per week (both at 20 mg). If this applies to you, your doctor will explain on which days of the week you should take your dose.
Packaging and Multiple Tablets
Evrenzo is supplied in perforated blister packs containing 12 tablets (4 weeks’ supply at three times weekly dosing), divided into 4 rows of 3 tablets. Each row corresponds to one week of treatment. If your prescribed dose requires more than one tablet strength, you may need to take tablets from multiple blister packs on each dosing day. Your doctor will explain exactly how many tablets to take.
Missed Dose
What to Do If You Miss a Dose
Never take a double dose to make up for a missed dose.
If more than 24 hours until your next planned dose: Take the missed dose as soon as possible and take the next dose on the next scheduled day.
If less than 24 hours until your next planned dose: Skip the missed dose entirely and take the next dose on the next scheduled day.
Overdose
If you have taken too many tablets or a higher dose than prescribed, contact your doctor immediately. An overdose of Evrenzo could potentially lead to an excessive increase in red blood cells, making the blood thicker. This can cause life-threatening problems with the heart or blood vessels, including blood clots. Seek immediate medical attention if you suspect an overdose.
Stopping Evrenzo
Do not stop taking Evrenzo unless your doctor tells you to. If your haemoglobin levels become too high, your doctor may temporarily pause your treatment and will inform you when and at what dose to restart. Stopping without medical supervision could allow your anaemia to worsen, leading to a return of symptoms such as fatigue, weakness, and shortness of breath.
What Are the Side Effects of Evrenzo?
The most common side effects of Evrenzo include elevated potassium levels, high blood pressure, nausea, diarrhoea, and peripheral oedema (swelling). Serious but less common side effects include blood clots (DVT, pulmonary embolism, vascular access thrombosis), seizures, stroke, sepsis, and thrombocytopenia.
Like all medicines, Evrenzo can cause side effects, although not everybody gets them. Some side effects can be serious and require immediate medical attention. If you experience any of the serious side effects listed below, contact your doctor immediately.
- Blood clots in the leg veins (deep vein thrombosis) – may affect up to 1 in 10 people
- Blood clots in the lungs (pulmonary embolism) – may affect up to 1 in 100 people
- Haemodialysis access thrombosis – may affect more than 1 in 10 people using a fistula or graft for dialysis
- Stroke (cerebrovascular event) – may affect up to 1 in 100 people
- Low platelet count (thrombocytopenia) – may affect up to 1 in 10 people; watch for unexplained bruising, tiny red spots on the skin, prolonged bleeding, or blood in urine or stool
- Seizures – may affect up to 1 in 10 people
- Sepsis (serious or life-threatening infection) – may affect up to 1 in 10 people
- Exfoliative dermatitis (redness and skin peeling over a large body area) – frequency unknown
Very Common
May affect more than 1 in 10 people
- Increased potassium levels (hyperkalaemia)
- High blood pressure (hypertension)
- Nausea
- Diarrhoea
- Swelling due to fluid retention in the limbs (peripheral oedema)
Common
May affect up to 1 in 10 people
- Difficulty sleeping (insomnia)
- Headache
- Vomiting
- Constipation
- Low platelet count (thrombocytopenia)
Uncommon
May affect up to 1 in 100 people
- Increased bilirubin levels in the blood
Reported (Frequency Unknown)
Reported from post-marketing surveillance
- Decreased thyroid function (hypothyroidism)
- Elevated copper levels in the blood
Misuse of Evrenzo (taking higher doses than prescribed) can lead to an excessive increase in red blood cell count, making the blood thicker. This can cause life-threatening complications affecting the heart and blood vessels. Always take Evrenzo exactly as prescribed by your doctor.
If you experience any side effects not listed here, or if any side effect becomes severe or persistent, contact your doctor or pharmacist. Reporting suspected side effects helps ensure ongoing monitoring of the medicine’s benefit-risk balance.
How Should You Store Evrenzo?
Store Evrenzo at room temperature with no special storage conditions required. Keep it out of the sight and reach of children. Do not use after the expiry date printed on the packaging.
Evrenzo does not require any special storage conditions. Keep the tablets in their original blister packaging until you are ready to take them. Check the expiry date (marked “EXP”) on the carton and blister before taking any tablet. The expiry date refers to the last day of the stated month.
Do not flush unused tablets down the toilet or throw them in household waste. Return any unused or expired medication to your pharmacy for safe disposal. These measures help to protect the environment from pharmaceutical contamination.
What Does Evrenzo Contain?
Each Evrenzo tablet contains the active ingredient roxadustat. It is available in five strengths: 20 mg, 50 mg, 70 mg, 100 mg, and 150 mg. The tablets are red, film-coated, and embossed with the tablet strength on one side.
Active Ingredient
The active substance is roxadustat. Each tablet contains the stated amount of roxadustat: 20 mg, 50 mg, 70 mg, 100 mg, or 150 mg depending on the tablet strength prescribed.
Inactive Ingredients (Excipients)
The other ingredients are:
- Tablet core: lactose monohydrate, microcrystalline cellulose (E460), croscarmellose sodium (E468), povidone (E1201), magnesium stearate (E470b)
- Film coating: polyvinyl alcohol (E1203), talc (E553b), macrogol (E1521), allura red AC aluminium lake (E129), titanium dioxide (E171), lecithin (soya) (E322)
Evrenzo contains lactose (milk sugar), soya lecithin (with potential for trace peanut cross-contamination), and allura red AC (an azo dye, E129). Patients with known allergies to peanuts, soya, or azo dyes should not take this medicine. Patients with lactose intolerance should inform their doctor before starting treatment.
Tablet Appearance and Packaging
20 mg: Red, oval, film-coated tablets embossed with “20” on one side.
50 mg: Red, oval, film-coated tablets embossed with “50” on one side.
70 mg: Red, round, film-coated tablets embossed with “70” on one side.
100 mg: Red, oval, film-coated tablets embossed with “100” on one side.
150 mg: Red, almond-shaped, film-coated tablets embossed with “150” on one side.
Evrenzo is available in perforated unit-dose PVC/aluminium blister packs containing 12 × 1 film-coated tablets and 36 × 1 film-coated tablets. Not all pack sizes may be marketed in your country.
Marketing Authorisation Holder
Astellas Pharma Europe B.V., Sylviusweg 62, 2333 BE Leiden, Netherlands.
How Does Evrenzo Work in the Body?
Evrenzo works by inhibiting HIF prolyl hydroxylase enzymes, which stabilises hypoxia-inducible factors (HIF). This mimics the body’s natural response to low oxygen levels, leading to increased erythropoietin production, improved iron absorption and mobilisation, and ultimately greater red blood cell production.
To understand how Evrenzo works, it is helpful to understand how the body normally responds to low oxygen levels. When tissues experience reduced oxygen supply (hypoxia), the body activates a powerful response system centred on hypoxia-inducible factors (HIFs). These are transcription factors – proteins that control the expression of specific genes. When activated, HIFs switch on genes involved in erythropoiesis (red blood cell production), iron metabolism, and oxygen delivery.
Under normal oxygen conditions, HIF-alpha subunits are constantly produced by cells but are rapidly tagged for destruction by prolyl hydroxylase domain (PHD) enzymes. These enzymes add hydroxyl groups to HIF-alpha, which marks it for recognition by the von Hippel-Lindau (VHL) protein, leading to rapid proteasomal degradation. This means HIF is continuously made and broken down, maintaining low levels under normal conditions.
At high altitude or during hypoxic conditions, the activity of PHD enzymes decreases because they require oxygen as a co-substrate. With less PHD activity, HIF-alpha accumulates, translocates to the nucleus, and activates the transcription of target genes. The most important of these is the erythropoietin (EPO) gene, which stimulates the bone marrow to produce more red blood cells. HIF also activates genes involved in iron absorption from the gut (by suppressing hepcidin) and iron mobilisation from storage sites, making more iron available for haemoglobin synthesis.
Roxadustat inhibits the PHD enzymes pharmacologically, mimicking the effect of hypoxia at the molecular level. By blocking the degradation of HIF-alpha, roxadustat allows HIF to accumulate and activate its target genes even under normal oxygen conditions. This triggers a coordinated erythropoietic response: increased EPO production, enhanced intestinal iron absorption, reduced hepcidin levels (allowing better iron mobilisation), and increased transferrin receptor expression. The net result is a more physiological stimulation of red blood cell production compared to the supraphysiological EPO peaks produced by injectable ESA therapy.
Pharmacokinetic Profile
After oral administration, roxadustat is rapidly absorbed with peak plasma concentrations reached approximately 2 hours after dosing. Food has minimal effect on the extent of absorption, so Evrenzo can be taken with or without food. However, co-administration with multivalent cation-containing products significantly reduces absorption (hence the 1-hour separation requirement).
Roxadustat is highly protein-bound (approximately 99%) in plasma. It is metabolised primarily by CYP2C8 and by glucuronidation via UGT1A9 and UGT2B7. The terminal elimination half-life is approximately 12 hours, which supports the three-times-weekly dosing schedule. The drug is eliminated primarily via the faeces (approximately 49%) and urine (approximately 39%). Roxadustat inhibits BCRP and OATP1B1 transporters, which accounts for its interactions with statins.
Frequently Asked Questions About Evrenzo
Evrenzo is used to treat symptomatic anaemia associated with chronic kidney disease (CKD) in adults. It works by stabilising hypoxia-inducible factors (HIF), which increases the body’s natural production of erythropoietin and red blood cells. Unlike traditional ESA injections, Evrenzo is taken orally as a tablet three times per week. It can be used in both dialysis-dependent and non-dialysis-dependent CKD patients.
Evrenzo is taken three times per week, with at least one day between each dose. You should take it on the same three days each week (for example, Monday, Wednesday, and Friday). The tablets should be swallowed whole and can be taken with or without food. You must wait at least 1 hour after taking phosphate binders or supplements containing calcium, iron, magnesium, or aluminium before taking Evrenzo.
The most serious side effects of Evrenzo include blood clots (deep vein thrombosis, pulmonary embolism, and vascular access thrombosis in dialysis patients), seizures, stroke, and sepsis (severe infection). If you experience sudden leg swelling, chest pain, shortness of breath, seizures, signs of stroke, or high fever with confusion, seek immediate medical attention. Your doctor will regularly monitor your haemoglobin and other blood parameters to minimise these risks.
Yes, Evrenzo can be used as an alternative to erythropoiesis-stimulating agents (ESAs) such as epoetin alfa or darbepoetin for treating anaemia in chronic kidney disease. Clinical trials (DOLOMITES, ROCKIES, PYRENEES) have shown that roxadustat is non-inferior to ESAs for maintaining haemoglobin levels. It offers the advantage of oral administration rather than injections. However, Evrenzo and ESAs should never be used at the same time. Your doctor will determine which treatment is most appropriate for you.
Phosphate binders and supplements containing calcium, iron, magnesium, or aluminium (known as multivalent cations) can bind to roxadustat in the gastrointestinal tract and significantly reduce its absorption. This means the drug will not be properly absorbed into your bloodstream and may not work effectively. To avoid this, you must always take Evrenzo at least 1 hour after these medications or supplements.
Evrenzo is not recommended during the first 6 months of pregnancy and is strictly contraindicated during the last 3 months (third trimester). Women of childbearing potential must use effective contraception during treatment and for at least one week after the last dose. If using hormonal contraception, an additional barrier method (condom or diaphragm) must also be used. Do not breastfeed while taking Evrenzo. Discuss family planning with your doctor before starting treatment.
References
This article is based on the following international medical guidelines, regulatory documents, and peer-reviewed sources. All medical claims adhere to evidence level 1A standards, based on systematic reviews of randomised controlled trials.
- European Medicines Agency (EMA). Evrenzo (roxadustat) – Summary of Product Characteristics. EMA product information database. Last updated September 2025.
- Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2022 Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney International. 2022;102(5s):S1–S64.
- Barratt J, Andric B, Tataradze A, et al. Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a Phase III, randomised, open-label, active-controlled study (DOLOMITES). Nephrology Dialysis Transplantation. 2021;36(9):1616–1628. doi:10.1093/ndt/gfab191
- Provenzano R, Shutov E, Erber B, et al. Roxadustat for anemia in patients with end-stage renal disease incident to dialysis. Nephrology Dialysis Transplantation. 2021;36(9):1629–1639.
- Csiky B, Schomburg A, Lu R, et al. Roxadustat for the maintenance treatment of anemia in patients with end-stage kidney disease on stable dialysis: a European Phase 3 randomized, open-label, active-controlled study (PYRENEES). Advances in Therapy. 2021;38(10):5361–5380.
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd list. Geneva: WHO; 2023.
- National Institute for Health and Care Excellence (NICE). Chronic kidney disease: assessment and management. NICE guideline [NG203]. Updated 2024.
- Sanghani NS, Haase VH. Hypoxia-inducible factor activators in renal anemia: current clinical experience. Advances in Chronic Kidney Disease. 2019;26(4):253–266.
Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, a group of licensed specialist physicians with expertise in nephrology, clinical pharmacology, and haematology.
Medical Writers
Board-certified physicians specialising in nephrology, haematology, and clinical pharmacology with documented academic and clinical experience.
Medical Reviewers
Independent review board ensuring clinical accuracy, adherence to international guidelines (KDIGO, EMA, NICE, WHO), and evidence level 1A standards.
All content follows the GRADE evidence framework and is reviewed against current international guidelines. We have no commercial funding or pharmaceutical sponsorship. For more information, see our editorial standards and medical team pages.